Background
Review
Properties of human embryonic stem cells
Derivation of human embryonic stem cell lines
Culture systems for embryonic stem cell propagation
Feeder cell monolayers
Feeder-free culture systems
System description/substrate
|
Cell type
|
Medium/supplements
|
SF
1
|
CD
2
|
XF
3
|
Culture period
|
Ref.
|
---|---|---|---|---|---|---|---|
Matrigel-mouse
| hESC | MEF –CM4 (basal medium DMEM+ KSR5) bFGF | Y | N | N | 180 days | [6] |
Matrigel-mouse
| hESC/ | DMEM/F12 | Y | N | N | 20 passages | [102] |
hiPSC | Dorsomorphin, IWP-2, bFGF,, TGF-β1, Activin | ||||||
ECM from embryoid body (e-ECM)
| hESC | TeSR2 | Y | Y | Y | 20 passages | [65] |
Human fibronectin
| hESC | DMEM/KSR | Y | N | N | >47 passages | [69] |
bFGF,, TGF-β1 (+/− LIF) | >180 days | ||||||
Laminin
| hESC | DMEM/KSR | Y | N | N | >20 passages | [51] |
bFGF, Activin | |||||||
Laminin,vitronectin, fibronctin and collagen IV (defined human ECM)
| hESc | TeSR1 | Y | N | Y | 11–25 passages | [70] |
Human placental ECM
| hESC | XF medium -Human plasma extract, with DMEM/F12 base, bFGF, TGFβ | N | N | Y | 39 passages | [68] |
Laminin isoforms 111,332,511
| hESC/ | MEF –CM (basal medium DMEM+ KSR5) | N | N | N | 10 passages | [72] |
hiPSC | |||||||
bFGF | |||||||
Laminin E8 fragments (LM-E8)
| hESC/ | mTeSR1, | Y | N | N | [74] | |
hiPSC | StemPro, | Y | N | N | 10–30 passages | ||
TeSR2 | Y | Y | Y | ||||
E-cadherin
| hESC | mTeSR1 | Y | N | N | >90 days | [79] |
hiPSC | |||||||
Laminin-511
| hESC | TeSR1 | Y | N | Y | 20 passages | [71] |
Laminin-521/E-cadherin matrix
| hESC | mTeSR1, | Y | N | N | 35 passages | [80] |
hiPSC | TeSR2, | Y | Y | Y | 12–15 passages | ||
Vitronectin
| hESC | mTeSR1 | Y | N | N | 10 passages | [82] |
Vitronectin- truncated
| hESC | E8 medium | Y | Y | Y | >25 passages | [83] |
hiPSC | |||||||
Fibronectin,, laminin and vitronectin
| hESC | DMEM/F12 +/− bFGF | Y | Y | Y | >24 passages | [87] |
Wnt/ID8 | |||||||
Recombinant human vitronectin
| hESC/ | E8 medium | Y | Y | Y | >30 passages | [85] |
Alginate microencapsulation
| hESC | MEF-CM (basal medium DMEM//KSR) | Y | N | N | 14 days | [126] |
Alginate encapsulation of hESC on
| bFGF | Y | N | N | 19 days | ||
Matrigel coated microcarriers
| |||||||
Aliginate-chitosan scaffold-3D
| hESC | DMEM/F12 + KSR + FBS + bFGF | Y | N | N | 21 days | [114] |
Alginate-chitosan microfiber scaffold-3D
| hiPSC | mTeSR1 | Y | N | N | 10 passages | [115] |
ROCK inhibitor | |||||||
Alginate encapsulated
| hESC | DMEM + KSR + bFGF | Y | N | N | >260 days | [116] |
Nanofibrillar cellulose
| hESC | mTeSR1 | Y | N | N | >26 days | [117] |
Aggregates/ in suspension Fibronectin and laminin present
| hESC | Neural basal medium.Neutrodoma-CS | Y | N | Y | >10 weeks | [128] |
bFGF, Activin, Neurotrophins BDNF, NT3, NT4 | |||||||
Aggregates in suspension
| hESC | mTESR1 | Y | N | N | 20–50 passages | [131] |
Polymer to prevent fusion/
| hiPSC/ | StemPro | Y | N | N | ||
DE-53 Matrigel coated cellulose microcarrier
| hESC | mTeSR1 | Y | N | N | 25 passages | [125] |
StemPro | Y | N | N | ||||
Artificial spider silk + vitronectin
| hESC/ | Nutirstem XF/FF | Y | N | Y | >30 passages | [93] |
hiPSC |
System description/substrate
|
Cell type
|
Medium/supplements
|
SF
1
|
CD
2
|
XF
3
|
Culture period
|
Ref
|
---|---|---|---|---|---|---|---|
Synthetic acrylate surfaces (PAS) with peptides: Vitronectin, bone sialo protein
| hESC | X -VIVO 10 | Y | N | Y | >10 passages | [89] |
bFGF,TGF-β1 | |||||||
Activin A | |||||||
Synthemax
4
| hiPSC | mTeSR1 | Y | N | N | 10 passages | [90] |
Synthemax
4
| hESC | mTESR1 | Y | N | N | 10–20 passages | [91] |
hiPSC | TESR2 | Y | Y | Y | |||
PSGro | Y | Y | Y | ||||
Nutristem XF | Y | N | Y | ||||
PMEDSAH
5
coated plates
| hESC | MEF-CM6
| N | N | N | 25 passages | [98] |
hCCM7
| N | N | Y | ||||
StemPro, | Y | N | N | ||||
mTeSR | Y | N | N | ||||
Alkanethiol with heparin binding proteins
| hESC | mTeSR1 | Y | N | N | >17 passages | [92] |
Rock inhibitor | |||||||
PMVE-alt-MA
8
| hiPSC | StemPro | Y | N | N | 5 passages | [94] |
APMAAm
9
hydrogels
| hESC | mTeSR1 | Y | N | N | 20 passages | [95] |
Polyethylene glycol hydrogels (PEG)
| hESC | DMEM/F12 + KSR | N | N | N | 9 days | [118] |
bFGF | |||||||
Hillex
10
microcarrier//suspension culture
| hESC | KSR-XF 10 | Y | N | Y | 6–14 days | [123] |
BRASTEM, | Y | N | Y | ||||
bFGF |
Medium
|
Source (Catalog#)
|
Basal medium/protein/select supplements
|
XF
|
CD
|
---|---|---|---|---|
ESF
| Cell Science & Technology | ESF basal medium// FAF-BSA conjugated with oleic acid | N | N |
FGF-2, LIF, insulin, transferrin, selenium, ascorbic acid, β-mercaptoethanol | ||||
mTeSR1
| Stemcell Technologies (#05850) | DMEM/F12/BSA | N | N |
bFGF, TGFβ, insulin, transferrin, cholesterol, lipids, pipecolic acid, GABA, β-mercaptoethanol | ||||
TeSR1
a
| Stemcell Technologies | DMEM/F12 /HSA | Y | N |
bFGF, TGFβ, insulin, transferrin, cholesterol, lipids, pipecolic acid, GABA, β-mercaptoethanol | ||||
TeSR2
| Stemcell Technologies (#05860) | DMEM/F12 // with recombinant HSA | Y | Y |
bFGF, TGFβ, insulin, transferrin, cholesterol, lipids, pipecolic acid, GABA, β-mercaptoethanol | ||||
E8
| Stemcell Technologies (#05940) | DMEM/F12 | Y | Y |
bFGF, TGFβ, insulin, transferrin, selenium, ascorbic acid | ||||
TESR-E8
| Stemcell Technologies (#05940) | Medium based on E8 formulation | Y | Y |
Nutristem XF/FF
| Stemgent (#010005) | Basal medium/ HSA | Y | N |
bFGF, TGFβ, insulin, transferrin | ||||
StemPro
| Life Technologies (#A1000701) | DMEM/F12/BSA | N | N |
bFGF, TGFβ, Activin, transferrin, LR3-IGF1, HRG1β | ||||
X-Vivo 10
| Lonza (#04380Q) | Basal medium/ HSA-pharmaceutical grade purification | Y | Y |
bFGF, hFLT3, transferrin, β-mercaptoethanol | ||||
Neutrodoma-CS
| Roche (11363743001) | Neural basal medium.Neutrodoma-CS/HSA | Y | N |
bFGF, Activin, Neurotrophins | ||||
PluriStem
| Millipore (#SCM130) | DMEM//F12, HSA | Y | N |
Activin-A, TGFβ1, b-FGF, lipids, insulin, transferrin, selenium | ||||
dorsomorphin (DM), IWP-2 | ||||
HyClone HyCellStem
| GE healthcare life sciences (#SR30003.KT) | DMEM//F12; BSA | Y | N |
bFGF, insulin, | ||||
PSGro
| Stem RD (#SC500M-1) | DMEM//F12 with recombinant HSA | Y | Y |
bFGF, TGFβ1, insulin,transferrrin, selenium, lipids | ||||
StemFit
| Ajinomoto Co. | Basal medium, HSA | Y | N |
bFGF |